A detailed history of Los Angeles Capital Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 64,696 shares of VRTX stock, worth $30.7 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
64,696
Previous 132,714 51.25%
Holding current value
$30.7 Million
Previous $55.5 Million 45.34%
% of portfolio
0.11%
Previous 0.19%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

SELL
$392.81 - $485.53 $26.7 Million - $33 Million
-68,018 Reduced 51.25%
64,696 $30.3 Million
Q1 2024

Apr 05, 2024

SELL
$407.69 - $446.08 $105 Million - $115 Million
-257,160 Reduced 65.96%
132,714 $55.5 Million
Q4 2023

Feb 06, 2024

SELL
$343.0 - $410.68 $12.8 Million - $15.3 Million
-37,196 Reduced 8.71%
389,874 $159 Million
Q3 2023

Nov 06, 2023

BUY
$338.18 - $362.46 $284,747 - $305,191
842 Added 0.2%
427,070 $149 Million
Q2 2023

Aug 03, 2023

SELL
$314.42 - $351.91 $9.72 Million - $10.9 Million
-30,927 Reduced 6.77%
426,228 $150 Million
Q1 2023

May 04, 2023

BUY
$283.23 - $323.1 $2.87 Million - $3.28 Million
10,144 Added 2.27%
457,155 $144 Million
Q4 2022

Feb 06, 2023

BUY
$285.76 - $321.48 $3.57 Million - $4.01 Million
12,485 Added 2.87%
447,011 $129 Million
Q3 2022

Nov 02, 2022

BUY
$273.83 - $305.53 $26.6 Million - $29.7 Million
97,060 Added 28.76%
434,526 $126 Million
Q2 2022

Aug 05, 2022

SELL
$234.96 - $292.55 $4.08 Million - $5.08 Million
-17,352 Reduced 4.89%
337,466 $95.1 Million
Q1 2022

May 06, 2022

BUY
$221.42 - $260.97 $11.7 Million - $13.8 Million
52,813 Added 17.49%
354,818 $92.6 Million
Q4 2021

Feb 03, 2022

BUY
$177.01 - $223.45 $26.2 Million - $33 Million
147,876 Added 95.94%
302,005 $66.3 Million
Q3 2021

Nov 08, 2021

SELL
$181.39 - $202.99 $2.76 Million - $3.09 Million
-15,228 Reduced 8.99%
154,129 $28 Million
Q2 2021

Aug 05, 2021

SELL
$187.49 - $221.1 $10.3 Million - $12.2 Million
-55,063 Reduced 24.54%
169,357 $34.1 Million
Q1 2021

May 05, 2021

SELL
$207.02 - $241.31 $17.1 Million - $19.9 Million
-82,644 Reduced 26.91%
224,420 $48.2 Million
Q4 2020

Feb 04, 2021

SELL
$207.01 - $276.09 $1.92 Million - $2.55 Million
-9,251 Reduced 2.92%
307,064 $72.6 Million
Q3 2020

Nov 02, 2020

SELL
$255.65 - $303.1 $4.24 Million - $5.03 Million
-16,597 Reduced 4.99%
316,315 $86.1 Million
Q2 2020

Aug 05, 2020

BUY
$225.48 - $295.8 $5.05 Million - $6.63 Million
22,412 Added 7.22%
332,912 $96.6 Million
Q1 2020

May 04, 2020

BUY
$199.77 - $247.81 $876,990 - $1.09 Million
4,390 Added 1.43%
310,500 $73.9 Million
Q4 2019

Feb 07, 2020

SELL
$166.71 - $223.91 $12.9 Million - $17.3 Million
-77,453 Reduced 20.19%
306,110 $67 Million
Q3 2019

Nov 07, 2019

SELL
$166.23 - $187.09 $8.38 Million - $9.43 Million
-50,423 Reduced 11.62%
383,563 $65 Million
Q2 2019

Jul 29, 2019

SELL
$164.61 - $190.37 $164,610 - $190,370
-1,000 Reduced 0.23%
433,986 $79.6 Million
Q1 2019

Apr 25, 2019

SELL
$163.73 - $194.7 $1.15 Million - $1.36 Million
-7,000 Reduced 1.58%
434,986 $80 Million
Q4 2018

Feb 11, 2019

SELL
$151.91 - $192.21 $15 Million - $19 Million
-98,831 Reduced 18.27%
441,986 $73.2 Million
Q3 2018

Nov 05, 2018

BUY
$167.73 - $192.74 $278,264 - $319,755
1,659 Added 0.31%
540,817 $104 Million
Q2 2018

Jul 31, 2018

BUY
$145.72 - $169.96 $32.4 Million - $37.8 Million
222,318 Added 70.17%
539,158 $91.6 Million
Q1 2018

Apr 27, 2018

SELL
$151.6 - $177.13 $406,288 - $474,708
-2,680 Reduced 0.84%
316,840 $51.6 Million
Q4 2017

Feb 05, 2018

BUY
$137.28 - $155.55 $32.1 Million - $36.4 Million
234,181 Added 274.41%
319,520 $47.9 Million
Q3 2017

Nov 06, 2017

BUY
$148.13 - $162.24 $12.1 Million - $13.3 Million
81,727 Added 2262.65%
85,339 $13 Million
Q2 2017

Aug 09, 2017

BUY
N/A
3,612
3,612 $465,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.